This article explores 7 key benefits of Risdiplam Powder API, the first oral SMA therapy approved for all age groups. It covers universal applicability across SMA Types 1/2/3, genetic root cause correction via SMN2 splicing modulation, superior practicality over invasive SMA therapies, stable formulation advantages for global supply, manageable safety profile, ultra-high purity standards, and why Shaanxi Sunrise is the ideal B2B partner. Backed by clinical trial data and pharmaceutical expertise, it’s a critical guide for B2B buyers and pharmaceutical innovators.